NAD+ Research Review: What the Studies Show, and Where They Stop

Amber glass vials and a spectrophotometer cuvette on a white bench, with a faint dinucleotide structure and an ultraviolet absorbance curve behind them

Few molecules in the research catalogue carry as much secondary commentary as this one, and few have a primary literature split so cleanly in two. On one side is settled biochemistry: NAD+ is a coenzyme every cell uses. On the other is a younger, noisier field asking what happens when its levels change. This review of NAD+ research separates those two bodies of work, summarises what the cited studies measured, and marks where the record stops. It is a literature review of a catalogue compound, not a guide to using one.

What NAD+ is, chemically

Nicotinamide adenine dinucleotide is an endogenous coenzyme, not a peptide. Structurally it is two nucleotides, one carrying adenine and one carrying nicotinamide, joined through a pyrophosphate bridge. The oxidised form, NAD+, accepts a hydride and becomes NADH; the pair shuttles electrons through the redox reactions of energy metabolism. A phosphorylated relative, NADP+/NADPH, serves the biosynthetic and antioxidant side of the cell, including the recycling of glutathione.

That redox role is textbook chemistry and is not where the debate lives. The debate starts with the second thing NAD+ does.

NAD+ research: the main threads

A consumed substrate, not only a carrier

In redox chemistry NAD+ is recycled, not used up. Several enzyme families, however, consume it outright. The review by Covarrubias et al., 2021 describes sirtuins, poly(ADP-ribose) polymerases (PARPs) and CD38 as NAD+-consuming enzymes, and links them to DNA repair, chromatin regulation and immune cell function. This is the mechanistic bridge most of the field depends on: if enzymes that regulate gene expression and genome maintenance draw on the same pool, the size of that pool becomes a variable worth measuring.

Reported decline in tissue levels

The same review collects reports that tissue NAD+ levels fall with age in rodents and in humans. That is an observational finding about measured concentrations. It does not, by itself, establish that the fall causes anything, or that reversing it would change any outcome; those are separate questions with separate evidence requirements, and the reviews' broader speculative claims are not repeated here.

The in vivo record for NAD-raising molecules

A widely cited Cell Metabolism review (Rajman, Chwalek and Sinclair, 2018) gathers animal studies of molecules that raise NAD+ levels. Its value for a reader is as a map of which models were used and which precursors were tested. Its stronger interpretive statements about animal disease models are the authors' synthesis, and the authorship includes researchers active in commercial development of these molecules, which is worth knowing when weighing tone against data.

Human trials, almost all of precursors

Here the literature changes subject. Many human studies of raising NAD+ did not use NAD+ at all; they used oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). In a randomised crossover trial, Martens et al., 2018 reported that chronic NR supplementation was tolerated and elevated NAD+ in healthy middle-aged and older adults. A 2025 systematic review and meta-analysis of NR and NMN trials (Prokopidis et al., 2025) found no significant effect on skeletal muscle mass, strength or gait speed in adults over 60.

Read together, those two papers describe the state of the human file fairly: raising measured NAD+ metabolites with a precursor is achievable in small trials, and functional outcomes have so far been mixed or null.

Where the evidence stops

  • The molecule studied is usually not NAD+. Human data are dominated by precursors with their own absorption and conversion pathways. Results for NR or NMN are not results for NAD+, and the reverse also holds.
  • Biomarker is not outcome. A higher blood NAD+ metabolite level is a measured change in a biomarker. The meta-analytic evidence on muscle function in older adults did not show a corresponding functional change.
  • Animal-to-human distance. The most striking findings in the review literature come from rodents. Model physiology, study length and the specific precursor all limit transfer.
  • Regulatory status. NAD+ is not an FDA-approved drug for any indication. It is an endogenous metabolite with an investigational research literature.

The honest summary: well-understood biochemistry, a plausible enzyme-substrate story connecting NAD+ to sirtuins, PARPs and CD38, small precursor trials that move a biomarker, and no consistent functional result to report.

How an NAD+ lot is characterised

Because NAD+ is a nucleotide rather than a peptide, its analytical profile differs from most of the catalogue. The adenine ring absorbs strongly in the ultraviolet, so reverse-phase or ion-pair HPLC with UV detection near 260 nm resolves NAD+ from related species. The impurities that matter are chemical relatives: NADH (the reduced form), nicotinamide and ADP-ribose from hydrolysis of the pyrophosphate-linked glycosidic bond, and free adenine nucleotides. Mass spectrometry confirms the molecular mass against the expected value of roughly 663 Da for the oxidised form.

Each lot's certificate of analysis states its measured purity and identity; that lot-specific document, not a catalogue figure, is what applies to a given vial. Our guide to reading a certificate critically covers what a credible one contains. NAD+ is sensitive to moisture and light, which is why the vial is stored at −20 °C, desiccated and protected from light.

Formats and specification

The catalogue lists NAD+ in three containers: the lyophilised NAD+ vial, a 10 mL NAD+ spray bottle with pump and overcap, and a hinged tin of NAD+ dissolving strips. These are container descriptions only; nothing in this article describes how any format is used.

FieldValue
Catalogue nameNAD+
IdentityNicotinamide adenine dinucleotide, oxidised form (a coenzyme, not a peptide)
CategoryResearch compounds
House codesCS-NAD-500 (500 mg vial), CS-NAD-1000 (1000 mg vial), CS-NAD-SP-500 (spray, 10 mL), CS-NAD-ST-30 (30 strips)
Vial storage−20 °C, desiccated, protect from light
Spray storage2 to 8 °C, protect from light
Strip storageRoom temperature, sealed, away from moisture
Lot documentationHPLC-UV identity and measured purity, mass confirmation, per lot
Evidence stageEndogenous metabolite; investigational, with precursor trials in people

For how NAD+ sits next to the mitochondrial peptides, see our review of SS-31, MOTS-c and NAD+; for another mitochondrial-genome story, see the humanin research review.

Frequently asked questions

Is NAD+ a peptide?

No. It is a dinucleotide coenzyme built from adenine and nicotinamide nucleotides. It is catalogued alongside research peptides, but its chemistry, analysis and literature are those of a nucleotide.

What does most human NAD+ research actually test?

Mostly oral precursors such as nicotinamide riboside and nicotinamide mononucleotide. Those trials report raised NAD+ metabolites; a 2025 meta-analysis found no significant effect on muscle mass, strength or gait speed in adults over 60.

Why are sirtuins, PARPs and CD38 always mentioned?

Because they consume NAD+ as a substrate rather than recycling it, which links the size of the cellular NAD+ pool to DNA repair, chromatin regulation and immune signalling in the published literature.

What should an NAD+ certificate show?

The lot number, an HPLC result stating measured purity, and a mass result confirming identity. Because NADH, nicotinamide and ADP-ribose are the expected relatives, a chromatogram that resolves them is more informative than a single number.

See it in the catalogue: NAD+.

For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.

California Standard Peptides

Your cart

0 items · free shipping over $200.00

Your cart is empty.

Buy 2 of a vial and save 10%, 3 and save 15%. Research sets are 15% off, and shipping is free over $200.00.

First order

20% off your first order.

Join the list for first word on new lots, restocks and member pricing. Your code arrives by email and applies by itself at checkout.

One code per email, for your first order. By signing up you agree to get emails from us. Unsubscribe anytime.

For laboratory research use only. 21+.